Article
Source: Campus Sanofi
19 Dec 2025

Unmet needs

Author: Sanofi

Editorial Team

Unmet needs

Current therapies: Gaps in disease control and persistent burden. While current therapies for ITP, wAIHA, and SCD may target specific immune pathways, they often fail to address the complex immune dysregulation underlying these diseases or are hindered by safety and tolerability concerns.

Class	MOA	Limitations and AEs

Streoids^1-3	Broad immunosuppression	• Avoid long-term use due to safety concerns
IVIg and Anti-D^3-5	Blockade of FcRs, targeting autoantibody-mediated destruction	• Transient results
Hematopoietic growth factors⁴	Simulate production and maturation of blood cells	• Do not impact B cells or address autoantibody production or inflammation
Biologics^1,6,7	Target specific cells or cytokines	• Might not address the multiple dysregulated pathways involved
First-generation kinase inhibitors¹	Block intracellular kinase signaling	• Can lead to off-target effects due to limited selectivity, resulting in safety concerns

Advances in kinase inhibitor design have led to the development of more selective agents, with the goal of reducing off-target effects¹

Multi-immune modulation: A comprehensive yet targeted approach for complex immune dysregulation

Abbreviations:

FcR, Fc receptor; IVIg, intravenous immune globulin; ITP, immune thrombocytopenia; MOA, mechanism of action; SCD, sickle cell disease; wAIHA, warm autoimmune hemolytic anemia. QoL, quality of life, TE, thromboembolism

References:

MAT-KW-2600101-V1-Mar-2026

Related